Tagrisso is at the center of AstraZeneca’s oncology resurgence. The drug, which first won approval in the U.S. in 2015, is the company’s second highest selling product, after the diabetes and kidney disease treatment Farxiga.
It has become a go-to treatment for EGFR-mutated lung cancers, which make up about 15% of the estimated 165,000 or so people who are diagnosed with non-small cell lung cancer each year. Over time, AstraZeneca has secured expanded clearance for its use earlier in metastatic treatment, as well as a role in the “adjuvant,” or after surgery, setting.
